Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Oct;87(10):1078-85.
doi: 10.1111/j.1349-7006.1996.tb03113.x.

In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors

Y Tsutsumi  1 , S Tsunoda, Y Kaneda, H Kamada, T Kihira, S Nakagawa, Y Yamamoto, Y Horisawa, T Mayumi
Affiliations

In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors

Y Tsutsumi et al. Jpn J Cancer Res. 1996 Oct.

Abstract

We previously reported that the optimally PEGylated tumor necrosis factor-alpha (MPEG-TNF-alpha), in which 56% of the TNF-alpha-lysine amino groups were coupled with polyethylene glycol (PEG), had about 100-fold greater anti-tumor effect than native TNF-alpha. Here, we assessed the usefulness of MPEG-TNF-alpha as a systemic anti-tumor therapeutic drug, using B16-BL6 melanoma and colon-26 adenocarcinoma, which have been reported to be resistant to TNF-alpha in vivo, as compared with Meth-A fibrosarcoma. MPEG-TNF-alpha markedly inhibited the growth of both tumors without causing any TNF-alpha-mediated side-effects, whereas native TNF-alpha had no anti-tumor effects and caused adverse side-effects. In addition, MPEG-TNF-alpha drastically inhibited the metastatic colony formation of B16-BL6 melanoma. MPEG-TNF-alpha may, thus, be a potential systemic anti-tumor therapeutic agent.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. ) Nobuhara , M. , Kanamori , T. , Ashida , Y. , Ogino , H. , Horisawa , Y. , Nakayama , K. , Asami , T. , Iketani , M. , Noda , K. , Andoh , S. and Kurimoto , M.The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor . Jpn. J. Cancer Res. , 78 , 193 – 201 ( 1987. ). - PubMed
    1. ) Manda , T. , Shimomura , K. , Mukumoto , S. , Kobayashi , K. , Mizota , T. , Hirai , O. , Matsumoto , S. , Oku , T. , Nishigaki , F. , Mori , J. and Kikushi , H.Recombinant tumor necrosis factor‐α: evidence of an indirect mode of antitumor activity . Cancer Res. , 47 , 3707 – 3711 ( 1987. ). - PubMed
    1. ) Debs , R. J. , Fuchs , H. J. , Philip , R. , Brunette , E. N. , Duzgunes , N. , Shellito , J. E. , Liggitt , D. and Patton , J. R.Immunomodulatory and toxic effects of free and liposome‐encapsulated tumor necrosis factor α in rats . Cancer Res. , 50 , 375 – 380 ( 1990. ). - PubMed
    1. ) Blick , M. , Sherwin , S. A. , Rosenblum , M. and Gutterman , J.Phase I study of recombinant human tumor necrosis factor in cancer patients . Cancer Res. , 47 , 2986 – 2989 ( 1987. ). - PubMed
    1. ) Moritz , T. , Niederle , N. , Baumann , J. , May , D. , Kurschel , E. , Osiek , R. , Kempeni , J. , Schlickl , E. and Schmidt , C. G.Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease . Cancer Immunol. Immunother. , 29 , 144 – 150 ( 1989. ). - PMC - PubMed

Publication types

LinkOut - more resources